A 43-year-old man’s rare autoimmune brain disorder hid behind a cocaine-use diagnosis for weeks until a delayed antibody test revealed anti-IgLON5 disease, Cureus reported this week.
The case illustrates how substance-use history can truncate a neurological workup. The patient presented with transient left-sided numbness, dysarthria, and choreiform movements. Initial imaging, EEG, and toxicology were unremarkable.
Clinicians attributed an acute worsening of movements to recent cocaine exposure and discharged him while a serum autoimmune panel was pending. Seventeen days later, that panel returned positive for IgLON5 antibodies at a titer of 1:1920. A lumbar puncture confirmed the antibody in cerebrospinal fluid at 1:128.
“When a patient with unrecognized anti-IgLON5 disease presents after cocaine use, the exposure offers a ready explanation for the acute syndrome, and the diagnostic process may close before the underlying disorder is considered,” the authors wrote in the case report.
Positive Drug Screen Does Not Exclude Autoimmune Neurological Disease
- A positive drug screen does not rule out a concurrent autoimmune neurological disease; both can exist simultaneously.
- Anti-IgLON5 disease often mimics more common conditions like multiple system atrophy or drug-induced movement disorders, delaying correct treatment.
- Immunotherapy (steroids and IVIG) can produce rapid, dramatic improvement in sleep and movement symptoms, even years after onset.
The Diagnostic Trap: Cocaine as a Cognitive Stopper
Cocaine is a well-established cause of hyperkinetic movements, including chorea, akathisia, and myoclonus. In this patient, the temporal link between reported use and symptom escalation created a satisfying clinical narrative: substance-induced movement disorder. The team discharged him on day three. The diagnosis only reversed when the serum antibody panel — sent during the first admission but resulted weeks later — flagged the rare autoantibody.
Anti-IgLON5 disease sits at the intersection of autoimmunity and neurodegeneration. Patients carry a strong genetic association with HLA-DRB1*10:01 and HLA-DQB1*05:01 alleles, yet post-mortem exams reveal a primary tauopathy targeting the hypothalamus and brainstem tegmentum. This dual nature complicates classification and fuels diagnostic misses.
Epidemiology and Phenotype: What the Numbers Show
A 2023 systematic review of 285 published patients quantified the syndrome’s heterogeneity. Sleep abnormalities led at 76.5%, followed by bulbar dysfunction at 61.4% and movement disorders at 56.1%. In a dedicated movement-disorder cohort of 72 patients, 87% had at least one movement disorder, with a median of three distinct phenomenologies per patient. Chorea occurred in 33%; other hyperkinetic features — myoclonus, akathisia, myorhythmia, myokymia, abdominal dyskinesias — appeared in 36%.
| Clinical Feature | Prevalence in Systematic Review (n=285) | Prevalence in Movement Cohort (n=72) |
|---|---|---|
| Sleep abnormalities | 76.5% | Not reported |
| Bulbar dysfunction | 61.4% | Not reported |
| Movement disorders | 56.1% | 87% |
| Chorea (subset of movement) | Not reported | 33% |
Antibody testing adds another layer of complexity. In the original series of 16 patients with paired serum and CSF samples, 14 were positive in both compartments. Two patients had antibodies in serum only; both presented with a progressive supranuclear palsy-like phenotype. A negative result in one compartment does not exclude the diagnosis, and paired testing is recommended when clinical suspicion is high.
Treatment Resolved Movement and Sleep Symptoms but Insomnia Persisted
The patient received intravenous methylprednisolone 1 g daily for three days, followed by a five-day course of intravenous immunoglobulin (IVIG). By day 21, choreiform movements and dream-enactment behaviors had resolved. The patient reported the longest, most restorative sleep in years.
At a 96-day follow-up, movement, speech, and cognitive symptoms remained in remission on maintenance IVIG every four weeks. However, insomnia persisted at three to four hours per night, attributed to residual encephalitic injury, nocturnal urinary urgency, and hypertensive headaches.
References
- Sabater L, et al. Anti-IgLON5 disease was first described in 2014 as a novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5 in a case series with characterisation of the antigen and post-mortem study. 2014.
- Gastaut H, et al. 2018.
- Högl B, et al. A systematic review included 285 patients with anti-IgLON5 disease.
- Movement disorder phenomenology was evaluated in a cohort of 72 patients with anti-IgLON5 disease. 2022.
- Cureus. Anti-IgLON5 Disease Masquerading as a Cocaine-Induced Hyperkinetic Movement Disorder: A Case Report.